At a glance
ClinicalIndex Comparison Record- ✓Type 2 diabetes diagnosed by physician for ≥1 year
- ✓Current HbA1c 6.5-8.0%
- ✓On stable (≥3 months) lifestyle or oral glucose-lowering medications
- ✓Blood pressure <160/99 mmHg
- ✕Taking exogenous insulin or SGLT2 inhibitors
- ✕Following ketogenic diet, low-calorie diet, periodic fasting, or ketogenic supplements
- ✕Competitive endurance athlete
- ✕Disorders of fat metabolism, chronic pancreatitis, gastric bypass surgery, or gallbladder disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Acute Exogenous Oral Ketone Supplementation on Blood Glucose Levels in Type 2 Diabetes
In Brief
A clinical study evaluating Ketone monoester and Placebo for Ketosis and Type 2 Diabetes. Completed, enrolled 19 participants across 1 site.
Detailed Summary
Exogenous ketone supplements are proposed to have glucose-lowering potential, provide an alternative fuel for the brain and to enhance cognitive function. No studies have tested whether exogenous ketones can lower blood glucose in people with type 2 diabetes. In addition, the impact of exogenous ketones on brain blood flow, cognitive function or brain-derived neurotrophic factor in humans is unknown. The purpose of this study is to determine if acutely ingesting exogenous ketones, in the form of a ketone monoester drink, can lower glucose and improve measures of brain/cognitive function in humans with type 2 diabetes. Participants will consume a ketone monoester drink or placebo with blood samples, brain blood flow, and cognitive function assessed over 180 minutes. The researchers will also test how the ketone monoester drink impacts appetite and measures of inflammation.
Study Details
Timeline
Interventions
Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior to assessment of outcomes.
Acute ingestion of taste-matched placebo prior to assessment of outcomes.